This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arena Pharma Sinks Under Weight Of Vivus' Troubles

Stocks in this article: ARNA VVUS

SAN DIEGO ( TheStreet) -- Jefferies analyst Thomas Wei is still an Arena Pharmaceuticals (ARNA - Get Report) bull, just not as much after slashing his sales forecast for the yet-to-be-launched obesity pill Belviq. Here's what Wei writes Wednesday:

We remain confident in the long-term potential for Belviq based on combination use with phentermine, but we are lowering our PT from $20 to $14, as we moderate our launch expectations for Belviq monotherapy following disappointing sales for competitor Qsymia.

"Moderate." That's sell-side analyst speak for, "Oh my god, my old forecast is so wrong."

Wei's "moderated" guess for Belviq sales in 2013 is now $35 million, down from $115 million. That's 70% "moderation" to his estimate, by the way.

In 2015, Wei now projects Belviq sales of $365 million, down from $700 million.

Vivus' (VVUS - Get Report) poor third-quarter financial report and honest (but generally downbeat) assessment of the challenges facing peddlers of new obesity pills has analysts and some investors in re-assessment mode.

Credit Suisse analyst Lee Kalowski was actually ahead of his peers warning about Vivus' slow Qsymia launch but he, too, had more cutting to do Wednesday. His new Qsymia 2013 sales forecast is $88 million, down from $165 million. He's not much more optimistic about Arena and Belviq:

We have updated our model, though we leave Belviq revenue forecasts unchanged, resulting in higher launch forecasts for Belviq relative to Qsymia. Belviq will have no REMS and will be available at the retail channel, but we are concerned that Eisai is launching Belviq initially with (a) an equally under-sized field force and (b) weaker monotherapy efficacy that leaves it positioned somewhat awkwardly in the market. Combination trial data is unlikely until at least 2015, which will prove too late if the initial launch underwhelms. Belviq's monotherapy response rate is around 40%, which could hinder the uptake of repeat use -- if the product is used in a similar manner as Qsymia, with many physicians putting only a few patients on the product at a time. Despite having split economics on Belviq, ARNA now trades at a substantial premium to VVUS.

The most worrisome disclosure by Vivus Tuesday was the fact that 30% of patients willing to try Qsymia and who get actually get a prescription from their doctor are not following through because the drug costs too much out of pocket. Insurance coverage for the drug is only 20% currently, not the 50%-plus estimated by third-party research firms. This trend is not a friend for Belviq, which is much less effective.

J.P. Morgan analyst Cory Kasimov writes Wednesday:

The Arena conference call was relatively uneventful in terms of providing additional details on the launch plans for Belviq (obesity). However, we see few signs that the early launch of Belviq will avoid the problems VVUS is currently experiencing with its weight loss drug, Qsymia (including slow uptake and a meaningful number of ptatients not filling their prescription due to a relatively high out-of-pocket cost). In fact, Belviq could well experience a more lackluster launch vs. Qsymia given the drug's more modest efficacy. These potential issues combined with minority economics currently prevent us from being more constructive on the name at this valuation.

Kasimov forecasts 2013 Belviq U.S. sales of $74 million growing to $481 million in 2016 - in other words, no blockbuster, particularly since Arena only gets approximately one-third of the drug's economics, the rest going to Eisai.

If you haven't already, read TheStreet contributor Nate Sadeghi's take on Arena and Vivus. The headline says it all, Arena Pharma Is Still A Good Short.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs